Compare Stocks → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AADINASDAQ:ALDXNASDAQ:ORMPNASDAQ:VAXX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.84-3.2%$2.06$1.55▼$8.60$45.17M0.62366,643 shs83,965 shsALDXAldeyra Therapeutics$3.91-0.5%$3.61$1.42▼$11.97$231.46M1.51585,790 shs452,218 shsORMPOramed Pharmaceuticals$2.35+0.9%$2.88$1.67▼$5.25$95.22M1.81168,113 shs31,031 shsVAXXVaxxinity$0.20-25.9%$0.65$0.19▼$3.10$25.35M2.39497,566 shs2.08 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-3.16%+2.79%-15.60%+7.60%-76.77%ALDXAldeyra Therapeutics-0.51%+1.03%+34.83%+30.33%-58.62%ORMPOramed Pharmaceuticals+0.86%-2.08%-19.24%+3.52%+3.52%VAXXVaxxinity-25.82%-54.52%-71.81%-70.89%-89.19%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi Bioscience2.1619 of 5 stars3.34.00.00.00.03.30.6ALDXAldeyra Therapeutics2.2257 of 5 stars3.53.00.00.02.52.50.0ORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVAXXVaxxinity1.5618 of 5 stars3.50.00.00.01.63.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience2.50Moderate Buy$24.671,240.58% UpsideALDXAldeyra Therapeutics3.00Buy$9.33138.70% UpsideORMPOramed PharmaceuticalsN/AN/AN/AN/AVAXXVaxxinity3.00Buy$7.003,400.00% UpsideCurrent Analyst RatingsLatest ORMP, VAXX, ALDX, and AADI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$24.35M1.86N/AN/A$4.29 per share0.43ALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/AORMPOramed Pharmaceuticals$1.34M71.06N/AN/A$4.04 per share0.58VAXXVaxxinity$70K362.14N/AN/A$0.11 per share1.82Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.44N/AN/AN/A-270.04%-52.53%-44.29%5/8/2024 (Estimated)ALDXAldeyra Therapeutics-$37.54M-$0.64N/AN/AN/AN/A-29.45%-24.24%5/2/2024 (Estimated)ORMPOramed Pharmaceuticals$5.53M$0.1416.79∞N/AN/A-7.15%-5.70%5/9/2024 (Estimated)VAXXVaxxinity-$56.93M-$0.45N/AN/AN/AN/A-192.58%-88.04%5/14/2024 (Estimated)Latest ORMP, VAXX, ALDX, and AADI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023VAXXVaxxinity-$0.13-$0.09+$0.04-$0.09N/AN/A3/13/2024Q4 2023AADIAadi Bioscience-$0.67-$0.60+$0.07-$0.60$6.46 million$6.33 million3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/A3/6/2024Q4 2023ORMPOramed Pharmaceuticals-$0.12-$0.08+$0.04-$0.49N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.724.48ALDXAldeyra TherapeuticsN/A6.646.64ORMPOramed PharmaceuticalsN/A3.063.06VAXXVaxxinity0.991.891.89OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%ALDXAldeyra Therapeutics59.71%ORMPOramed Pharmaceuticals12.73%VAXXVaxxinity82.95%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience35.80%ALDXAldeyra Therapeutics7.30%ORMPOramed Pharmaceuticals12.00%VAXXVaxxinity59.07%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience8924.55 million15.76 millionOptionableALDXAldeyra Therapeutics1558.90 million54.60 millionOptionableORMPOramed Pharmaceuticals1240.52 million35.66 millionOptionableVAXXVaxxinity57126.75 million51.88 millionNot OptionableORMP, VAXX, ALDX, and AADI HeadlinesSourceHeadlineWhy Is Vaxxinity (VAXX) Stock Down 58% Today?investorplace.com - April 22 at 8:40 AMVaxxinity Plans to Delist Shares From Nasdaqmarketwatch.com - April 19 at 7:30 PMVaxxinity Issues Shareholder Letterglobenewswire.com - April 19 at 6:53 PMVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stockglobenewswire.com - April 19 at 4:27 PMVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meetingglobenewswire.com - March 28 at 9:23 AMVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023investorplace.com - March 27 at 11:03 PMVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updatesglobenewswire.com - March 27 at 4:41 PMVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024globenewswire.com - March 7 at 10:32 AMVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levelsfinance.yahoo.com - February 15 at 2:41 PMVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Publishedfinance.yahoo.com - February 15 at 9:40 AMVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Publishedglobenewswire.com - February 15 at 8:00 AMVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024finance.yahoo.com - February 13 at 8:20 AMVaxxinity, UF Join Forces Against Neurodegenerative Diseasesfinance.yahoo.com - January 30 at 2:16 PMVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Floridafinance.yahoo.com - January 30 at 9:15 AMVaxxinity & UCF to Collaborate on Space Medicine Researchfinance.yahoo.com - January 19 at 3:05 PMVaxxinity Announces Collaboration on Space Medicine Research with University of Central Floridafinance.yahoo.com - January 18 at 8:33 AMVaxxinity to Present at the 2024 J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 12:34 PMThe Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinityfinance.yahoo.com - December 12 at 11:22 AMAlzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Othersmarkets.businessinsider.com - November 21 at 7:47 PMSeveral Alzheimer's vaccines enter clinical trials amid breakthrough treatments' successfoxnews.com - November 20 at 6:32 PMResearchers return to Alzheimer's vaccines, buoyed by recent drug successmsn.com - November 20 at 8:31 AMVaxxinity to Present at Upcoming November Medical and Investor Conferencesfinance.yahoo.com - November 13 at 7:50 PMVaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 8 at 9:19 AMPrivate companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap declinefinance.yahoo.com - October 10 at 4:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAadi BioscienceNASDAQ:AADIAadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Aldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Oramed PharmaceuticalsNASDAQ:ORMPOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.VaxxinityNASDAQ:VAXXVaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.